Shots:
The EMA’s CHMP has granted approvals to 1 Biologic and 3 new chemical entities in August 2025, leading to treatments for patients and advances in the healthcare industry
The major highlighted drug was Gilead’s Yeytuo has Secured the EC’s Approval for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV
PharmaShots has compiled a list of 4…
The rise of collagen supplements in wellness and beauty sectors underscores the importance of selecting the right collagen manufacturer. As consumers demand effective and trustworthy products, the choice of a manufacturer becomes a pivotal factor in brand success and consumer trust. This article delves into why choosing the right collagen manufacturer is essential for building…
Shots:
Enable Injections recently shared survey findings indicating that many oncology assets with strong commercial potential are often prematurely abandoned or deprioritized due to challenges in formulating small volumes (<3 mL) for subcutaneous delivery.
To address this need, Enable Injections developed enFuse, an innovative, hands-free, wearable drug delivery platform with a discreet, hidden needle that…
This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar, and DigiHealth. Check out our full report below:
AstraZeneca Reports P-III (FLAURA2) Trial Findings on Tagrisso Regimen to Treat EGFRm NSCLC
Read More: AstraZeneca
Eli Lilly Reports P-III (BRUIN CLL-313) Trial Data on Jaypirca for 1L…
Medical psychedelics are a fascinating field that modern science has yet to comprehend completely. Researchers are still digging up, trying to find evidence-based outcomes to tap into a whole new opportunity in psychiatry and mental health medicines
The September Edition unearths a brand-new perspective on psychedelics through engaging articles, illustrative infographics, trailing BioTrends, illuminating regulatory…
Last month, we explored four key trends shaping the biopharma industry in 2025. In this follow-up, we spotlight the evolving role of multi-omics analysis—a field rapidly transforming how diseases are understood, diagnosed, and treated.
In 2024, the global multi-omics market was valued at $2.72 billion and is projected to reach $9.91 billion by 2033, growing…
Shots:
PharmaShots has compiled a list of US FDA-approved drugs in the month of August 2025
The US FDA has approved a total of 5 new drugs, including 5 new molecular entities, leading to the treatment of patients and advances in the pharmaceutical industry
The major highlighted drug was Jazz Pharmaceuticals’ Modeyso, securing FDA approval…
Shots:
In this episode of the CXO Talks podcast, PharmaShots speaks with Rick Modi, CEO at Affinia Therapeutics
Driven by cutting-edge innovation, Affinia is pioneering and re-imagining adeno-associated virus serotype 9 (AAV9), a gene therapy delivery method for conditions affecting cardiac muscle, skeletal muscle, and the central nervous system
Rick articulates the diagnostic and therapeutic…
Shots:
The United States has about 38.4 million people living with diabetes, representing 11.6% of the total population. With growing prevalence, there is a significant unmet need for affordable diabetes medications.
Biocon Biologics recently announced the FDA approval of Kirsty, the first and only interchangeable biosimilar to NovoLog (Insulin Aspart).
Joshua Salsi, the Head of…
This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, COVID-19, Animal Health and Biosimilars. Check out our full report below:
Merck Reports P-III (VICTOR) Trial Data of Verquvo (Vericiguat) for Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Read More: Merck
AstraZeneca Reports P-III (BaxHTN) Trial Data on Baxdrostat…

